Herpes simplex infectious disease
MONDO:0004609A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)
Also known as: Simplexvirus caused disease or disorder, Simplexvirus disease or disorder, Simplexvirus infectious disease, herpes simplex, herpes simplex complex, herpes simplex infection, herpes simplex viral infection
38 clinical trials for this condition and its sub-types, 15 tagged with Herpes simplex infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Herpes simplex infectious disease
-
Genital herpes 8 trials
2 sub-types
-
Herpes simplex type 2 infectious disease 5 trials · 8 incl. sub-types
2 sub-types
-
Herpes labialis 5 trials
2 sub-types
-
2 sub-types
-
Herpes simplex virus keratitis 1 trial · 4 incl. sub-types
2 sub-types
- Endotheliitis 2 trials
- Stromal keratitis 1 trial
-
Herpes simplex encephalitis 2 trials
-
Herpes simplex dermatitis 0 trials
-
Herpetic whitlow 0 trials
-
A 20-Year-Old immune regulator faces its biggest test against cold sores
Disease control Recruiting nowThis trial tests whether 2LHERP, an immune regulator available for over 20 years, can reduce the number of cold sore outbreaks in adults who get at least six per year. Participants take one capsule daily for six months, then researchers compare outbreak rates over a year against …
Phase 4 • Sponsor: Labo'Life • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could a cold sore virus treatment save ICU pneumonia patients?
Disease control Recruiting nowThis study tests whether the antiviral drug acyclovir helps people on breathing machines who have pneumonia and also have herpes simplex virus (HSV) in their lungs. About 616 adults in intensive care will be randomly assigned to receive acyclovir or no antiviral treatment. The go…
Phase 3 • Sponsor: Jena University Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Daily acyclovir may stop herpes Flare-Ups in rheumatic patients
Prevention Recruiting nowThis study tests whether taking acyclovir daily can prevent herpes simplex outbreaks in people with autoimmune rheumatic diseases like lupus or rheumatoid arthritis. 62 participants will receive either acyclovir or a placebo for 12 months and be monitored for 24 months total. The…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Scientists hunt for genetic clues to severe viral infections
Knowledge-focused Recruiting nowThis study looks at people who have had unusually severe or long-lasting viral infections, like serious cases of herpes, HPV, or the flu. Researchers want to find out if these people have hidden immune system or genetic problems that make them more vulnerable. Up to 600 participa…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists track rare genetic disorder to unlock its secrets
Knowledge-focused Recruiting nowThis study follows 600 people with GATA2 deficiency, a genetic disorder affecting the immune system and other body systems. Researchers aim to understand the full range of health problems it causes and why it affects people differently. Participants will have yearly check-ups for…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for genetic clues behind rare, Life-Threatening EBV disease
Knowledge-focused Recruiting nowThis study aims to find genetic mutations that cause chronic active Epstein-Barr virus (CAEBV), a rare and serious disease mainly affecting children and young adults. Researchers will analyze blood and tissue samples from up to 50 patients and 150 relatives, plus anonymous donor …
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC